Indeed, while expression levels point towards APOBEC3B as the guilty party, the increase in cancer risk among germline APOBEC3B deletion carriers [5] and the increased burden of APOBEC-pattern mutations [6] attributed to APOBEC3A [7] seen in these patients highlights key unresolved issues. This evidence concerns the gene APOBEC3B and cancer.